The psychotic symptoms, delusions and hallucinations, are present in at least 30-40% of patients with Alzheimer's disease (AD). Psychotic symptoms in AD patients (AD+P) predict more rapid functional decline and premature institutionalization. Current treatments for AD+P are inadequate. We have hypothesized a polygenic model of AD+P. In preliminary tests of this hypothesis of this hypothesis, we have found that AD+P was significantly more frequent in patients with specific genotypes at the dopamine1 (D1) and D3 receptor loci (Sweet et a., 1998). Similarly, Holmes et al. (1998) reported an association in AD patients with variation in the serotonin/2A (5-HT2A) and 5-HT2C receptor genes. We propose to establish a cohort of 644 subjects, prospectively and longitudinally characterized with regard to psychosis phenotype, for examination of the genetic determinants of AD+P. Subjects with mild cognitive impairment, possible AD and probable AD will be evaluated at presentation to the Alzheimer's Disease Research Centers of the University of Pittsburgh and the University of Pennsylvania. Genetic material will be obtained. Neuropsychiatric assessments of psychotic symptoms will be conducted, with ratings on the CERAD Behavioral Rating Scale. Subjects without current or prior psychotic symptoms will be followed longitudinally with repeat assessments for psychotic symptoms every 6 months. Telephone assessments will be used for subjects unable to return to minimize incomplete data due to drop-outs. We project 20%-30% of the 644 subjects without psychosis at baseline will develop incident AD+P during the study interval. We hypothesize: 1) D1 receptor genotype will predict onset of AD+P; 2) D3 receptor genotype will predict onset of AD+P; 3) 5-HT2A receptor genotype will predict onset of visual hallucinations; 4) H-HT2C receptor genotype will predict onset of visual hallucinations. This study would be the first to prospectively evaluate the contribution of specific genes to predicting the onset of psychotic symptoms in any disorder. Replicated findings would provide a compelling rationale for family-based studies to address population stratification effects and for pursuit of the identified receptors as targets for drug development. Finally, establishing an AD cohort with prospectively determined psychosis phenotype will facilitate the research for novel risk genes as new genetic technologies become available.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
2P50AG005133-17
Application #
6345443
Study Section
Special Emphasis Panel (ZAG1-PKN-7 (J1))
Project Start
1985-09-30
Project End
2005-03-31
Budget Start
Budget End
Support Year
17
Fiscal Year
2000
Total Cost
$158,272
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Besser, Lilah M; Kukull, Walter A; Teylan, Merilee A et al. (2018) The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses. J Neuropathol Exp Neurol 77:717-726
Lingler, Jennifer H; Roberts, J Scott; Kim, Hyejin et al. (2018) Amyloid positron emission tomography candidates may focus more on benefits than risks of results disclosure. Alzheimers Dement (Amst) 10:413-420
Barnes, Josephine; Bartlett, Jonathan W; Wolk, David A et al. (2018) Disease Course Varies According to Age and Symptom Length in Alzheimer's Disease. J Alzheimers Dis 64:631-642
Krivinko, Josh M; Erickson, Susan L; Ding, Ying et al. (2018) Synaptic Proteome Compensation and Resilience to Psychosis in Alzheimer's Disease. Am J Psychiatry 175:999-1009
Lancour, Daniel; Naj, Adam; Mayeux, Richard et al. (2018) One for all and all for One: Improving replication of genetic studies through network diffusion. PLoS Genet 14:e1007306
Tudorascu, Dana L; Minhas, Davneet S; Lao, Patrick J et al. (2018) The use of Centiloids for applying [11C]PiB classification cutoffs across region-of-interest delineation methods. Alzheimers Dement (Amst) 10:332-339
DeKosky, Steven T; Jaffee, Michael; Bauer, Russell (2018) Long-term Mortality in NFL Professional Football Players: No Significant Increase, but Questions Remain. JAMA 319:773-775
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Snitz, Beth E; Wang, Tianxiu; Cloonan, Yona Keich et al. (2018) Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement 14:734-742

Showing the most recent 10 out of 667 publications